Navigation Links
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
Date:7/7/2009

gen environments (such as the damaged areas of the heart), they are committed to becoming muscle, and they are the only progenitor cell in the human body that normally develop the ability to contract making them more likely to restore contractile function of the damaged heart.

About Bioheart, Inc.

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could,"
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
2. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
6. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
7. Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
8. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
9. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...   Royal Philips (NYSE: ... of its portfolio of diagnostic X-ray solutions ... , ProGrade and PrimaryDiagnost[ii]. With new releases of ... U.S., and availability of all these solutions in ... innovative solutions designed to meet the needs and ...
(Date:11/26/2014)... 2014 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... previously announced concurrent financing transactions resulting in gross ... offering expenses, Lexicon anticipates net proceeds of approximately ... of: , a public offering of ... registration statement that has been declared effective by ...
(Date:11/26/2014)... -- Scott Steiger lives in St. Louis ... engineer for the past 20 years, he,s traveled extensively and prior ... been to six of the seven continents. Travel is a big ... Photo - http://photos.prnewswire.com/prnh/20141126/161077 So when ... good idea of what,s required. His latest creation is ...
Breaking Medicine Technology:Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2
... CVS Caremark (NYSE: CVS ) today ... of CVS/pharmacy effective October 1, 2011.  With more than ... and Puerto Rico, CVS/pharmacy is one of the largest ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) Cosby, 52, most recently served as ...
... Oncobiologics, Inc. and Fox Chase Cancer Center ... next-generation bi-specific antibody cancer platform with enhanced therapeutic ... is designed to handle multiple targets, representing a ... is now underway, with preclinical studies expected in ...
Cached Medicine Technology:CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 2CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 3Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 2Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 3
(Date:11/28/2014)... The Alternative Health Therapies ... five years. The industry has been buoyed by ... either alternative to conventional Western medicine or complementary ... David Whytcross, “industry revenue has been further boosted ... insurance membership.” Meanwhile, improving economic conditions following the ...
(Date:11/28/2014)... HealthDay Reporter , THURSDAY, Nov. 27, ... through cooking classes or at home, may make them more ... Cooking programs and classes for children seem to positively ... research. And, although the review didn,t look at long-term effects ... help children develop long-lasting healthy habits. "It ...
(Date:11/28/2014)... Mabel’s Labels , the market leader ... award-winning company established by four moms, today announced that ... Mumby have been honored with a 2014 RBC Canadian ... Award for Excellence in Entrepreneurship. , All 4 partners ... accepted the award on behalf of Mabel’s Labels at ...
(Date:11/28/2014)... Atlanta, Georgia (PRWEB) November 28, 2014 ... pecans and locally grown. With those passions driving them, ... is Georgia Grown. Having tried other pecans oils, they've ... near Pitts, Georgia to be exceptionally flavorful, retaining the ... , The same nutritional benefits found in ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 ARTAS robotic ... for the first time. PAI Medical Group hair transplant ... be performing a robotic hair transplant procedure in the ... A.M. , The first in Tennessee and one of ... Group now offers ARTAS robotic hair transplantation. Patients benefit ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2
... Misonix, Inc. (Nasdaq: MSON ), a developer ... Europe is used for the ablation of tumors and ... attendance and participation in the annual Diabetic Foot Global ... March 19-21, 2009. In addition to exhibiting its ...
... to Require Coverage of CT ColonographyRESTON, Va., May ... Medicare and Medicaid Services (CMS) to not cover ... virtual colonoscopy, exams is not supported by the ... of thousands of unnecessary deaths each year from ...
... ISELIN, N.J., May 12 Pharmos Corporation (Pink Sheets: PARS) ... 2009. The Company recorded a net loss of $3.7 million, ... to a net loss of $3.6 million, or $0.14 per ... totaled $2.9 million at March 31, 2009.The slight increase in ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today ... of its common stock pursuant to an effective shelf registration ... expects to use the net proceeds of the offering to ... million unsecured line of credit and for other general corporate ...
... for activity area at May 9 eventATLANTA, May 12 ... the first Bright Starts Kids for the Cure Korral at ... past Saturday, May 9 at Atlantic Station in Midtown Atlanta, ... a refreshing drink as they enjoyed fun activities like carnival ...
... Particularly Concerning in Older AmericansWASHINGTON, May 12 ... its third annual report on top longevity research ... the report here: , ... was joined by Carey Gleason, Ph.D., Associate Scientist/Geriatric ...
Cached Medicine News:Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 3Health News:CMS Denial of Coverage for Virtual Colonoscopy May Cost Lives 2Health News:CMS Denial of Coverage for Virtual Colonoscopy May Cost Lives 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 2Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 3Health News:Parents, Kids Enjoyed Kids Korral at Annual Komen Atlanta Race for the Cure 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 3Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 4
... contact between grant material and fracture ends ... bones., ,Grid-Like Format of Mesh Cathode Provides ... , ,The innovative Mesh Cathode of the ... and a scaffolding effect designed to increase ...
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
... a single use device that produces rapid, ... spread and vapor sealing of adjacent tissue ... BPH, without deep desiccation. Often referred to ... the Plasma-V gives the urologist the control ...
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips....
Medicine Products: